Fennec Pharmaceuticals (NASDAQ:FENC) Posts Quarterly Earnings Results, Misses Estimates By $0.62 EPS

Fennec Pharmaceuticals (NASDAQ:FENC) released its quarterly earnings results on Monday. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.56 by ($0.62), Zacks reports. Fennec Pharmaceuticals had a negative net margin of 2.30% and a negative return on equity of 53.38%.

Fennec Pharmaceuticals Price Performance

Shares of NASDAQ FENC opened at $6.88 on Monday. The stock has a market capitalization of $189.63 million, a PE ratio of -68.79 and a beta of 0.36. The business has a fifty day moving average price of $6.39 and a two-hundred day moving average price of $5.61. Fennec Pharmaceuticals has a fifty-two week low of $3.96 and a fifty-two week high of $11.49.

Insider Buying and Selling at Fennec Pharmaceuticals

In other Fennec Pharmaceuticals news, Director Rosty Raykov sold 10,000 shares of Fennec Pharmaceuticals stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $6.66, for a total value of $66,600.00. Following the completion of the transaction, the director now directly owns 76,294 shares of the company’s stock, valued at $508,118.04. The trade was a 11.59 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 31,186 shares of company stock valued at $203,389 in the last three months. Corporate insiders own 10.98% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Wedbush restated an “outperform” rating and issued a $13.00 price target on shares of Fennec Pharmaceuticals in a research note on Friday, December 20th. Stephens upgraded Fennec Pharmaceuticals to a “strong-buy” rating in a research note on Monday, November 18th. Finally, HC Wainwright restated a “buy” rating and issued a $13.00 price target on shares of Fennec Pharmaceuticals in a research note on Tuesday, December 17th.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.